InCred CIO flags hospitals, pharma and diagnostics picks; Pine Labs remains high conviction
InCred Asset Management CIO Aditya Khemka outlined healthcare preferences across hospitals, pharma and diagnostics, naming HCG, FDC, Thyrocare and Jeena Sikho Lifecare. He also identified payments platform Pine Labs as a high-conviction idea amid discussion on valuations, inflation and microfinance.
What happened
InCred Asset Management CIO Aditya Khemka outlines healthcare investment preferences spanning hospitals, pharma and diagnostics, citing HCG, FDC, Thyrocare and
Key facts
- Category III AIF
Why this matters
Strategic teams should assess partnership, acquisition or payments-integration opportunities around diagnostics, pharmacy and healthcare delivery, where investor attention may support premium asset valuations.
What to watch
- Hospital occupancy above prior guidance and sustained ARPOB expansion
- Diagnostic volume growth and improved B2C or preventive-testing mix
- Pharma regulatory approvals, product launches, price-control changes or adverse compliance observations
- Healthcare companies reporting margin expansion despite wage, rent and consumables inflation
- Pine Labs announcing IPO filings, new capital raises, strategic partnerships or improved profitability metrics
- Broad market rotation toward defensives amid macro uncertainty
- Microfinance stress or consumer-credit deterioration affecting fintech sentiment
- Track quarterly results, management commentary and institutional ownership changes in HCG, FDC, Thyrocare and Jeena Sikho Lifecare.
- Monitor hospital occupancy, ARPOB growth, diagnostics test volumes, pharma prescription momentum and operating-margin trends for confirmation.
- Watch Pine Labs for fundraising, IPO preparation, merchant-acquisition costs, payments take-rate trends and credit-product performance.
- Compare healthcare valuations against earnings revisions; rising prices without estimate upgrades would increase correction risk.
- Assess whether inflation and consumer-stress trends weaken discretionary healthcare demand or increase financing costs for expansion.